PMGC Holdings Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our Common Stock is currently quoted on The Nasdaq Capital Market under the symbol “ELAB.” We had 1,936,757 shares of Common Stock issued and outstanding as of December 31, 2025 (such number of Common Stock on a pre-reverse stock split basis, not reflecting the Company’s 1-for-4 reverse stock split which occurred on January 6, 2026 and 1-for-6 reverse stock split which occurred on March 10, 2026. Holders of Capital Stock As of December 31, 2025, we had 40 record holders of our Common Stock. Stock Option Grants As of December 31, 2025, the Company had no options outstanding to purchase Common Stock. As of December 31, 2025, no shares of Common Stock were issued under the 2025 Equity Incentive Plan. The 2025 Plan superseded the 2020 Plan and outstanding awards made under the 2020 Plan remained outstanding. As of December 31, 2025, there were 6 options outstanding from the 2020 Plan. Transfer Agent The transfer agent for our Common Stock is VStock Transfer, LLC. The transfer agent’s telephone number and address is (212) 828-8436 and 18 Lafayette Place Woodmere, New York 11598. Dividends To date, we have not declared or paid any dividends on our Common Stock. We currently do not anticipate paying any cash dividends in the foreseeable future on our Common Stock. Although we intend to retain our earnings, if any, to finance the exploration and growth of our business, the Board of Directors has the discretion to declare and pay dividends in the future. Payment of dividends in the future will depend upon our earnings, capital requirements, and any other factors that our Board deems relevant. Nasdaq Compliance On November 7, 2024, we received a letter from Nasdaq (the “Bid Price Deficiency Letter”) granting an exception for us to cure our lack of compliance with the bid price requirement in Listing Rule 5550(a)(2) (such rule, the “Bid Price Rule,” and such deficiency of the Bid Price Rule, the “Bid Price Deficiency”). In the Bid Price Deficiency Letter, Nasdaq permitted our continued listing on Nasdaq on the conditions that: (1) on or before December 26, 2024, we complete a reverse split at a ratio sufficient to maintain long-term compliance with the Bid Price Rule; and (2) on or before January 9, 2025, we demonstrate compliance with the Bid Price Rule. On January 14, 2025, the Company received a letter from Nasdaq (“Compliance Letter”) stating the Company had demonstrated compliance with the Bid Price Rule. Recent Sales of Unregistered Securities There were no equity securities of the registrant sold by the registrant during the period covered by this Annual Report that were not registered under the Securities Act. Item 6. [Reserved] Not applicable.